keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/28894571/vonoprazan-10-mg-daily-is-effective-for-the-treatment-of-patients-with-proton-pump-inhibitor-resistant-gastroesophageal-reflux-disease
#1
Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yasutoshi Kobayashi, Alan Kawarai Lefor, Hironori Yamamoto
Gastroesophageal reflux disease (GERD) is commonly treated by primary care physicians. Although proton pump inhibitors (PPI) have been the mainstay of GERD treatment for two decades, in some patients GERD is refractory to standard dose PPI for more than eight weeks and is referred to as PPI-resistant GERD. Vonoprazan, a novel competitive acid blocker, became available in Japan for the treatment of patients with GERD, and has greater acid inhibition than existing PPIs. The aim of the present study was to determine the effect of vonoprazan 10 mg daily on PPI-resistant GERD...
September 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28891137/treatment-of-helicobacter-pylori-infection-2017
#2
REVIEW
Anthony O'Connor, Dominique Lamarque, Javier P Gisbert, Colm O'Morain
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second-line setting, an increasing number of studies this year have shown excellent efficacy in first-line therapy. The efficacy of bismuth as a second-line after sequential and concomitant therapy was particularly noteworthy...
September 2017: Helicobacter
https://www.readbyqxmd.com/read/28884937/a-japanese-population-based-meta-analysis-of-vonoprazan-versus-ppi-for-helicobacter-pylori-eradication-therapy-is-superiority-an-illusion
#3
REVIEW
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, Hong Ling Wang
BACKGROUND: Vonoprazan (VPZ) is a novel acid suppressant that has been used in Helicobacter pylori (H. pylori) eradication therapies in recent years. However, the efficacy and safety of VPZ vs proton-pump inhibitor (PPI) in H. pylori eradication therapies remain controversial. OBJECTIVE: To perform a meta-analysis in order to assess the efficacy and safety of VPZ vs PPI for H. pylori eradication. MATERIALS AND METHODS: The PubMed, EMBASE, and Cochrane Library databases were searched up to July 10, 2017, for relevant randomized controlled trials (RCTs) and nonrandomized clinical studies (NRCTs)...
September 8, 2017: Helicobacter
https://www.readbyqxmd.com/read/28875498/comparative-study-of-effects-of-vonoprazan-and-esomeprazole-on-anti-platelet-function-of-clopidogrel-or-prasugrel-in-relation-to-cyp2c19-genotype
#4
Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura, Hiroaki Miyajima, Takahisa Furuta
Drug-drug interaction between anti-acid and anti-platelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole and vonoprazan. Using P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the anti-platelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers [14 CYP2C19 homo-extensive (homo-EMs), 9 hetero-extensive (hetero-EMs), and 8 poor metabolizers (PMs)]...
September 5, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28845910/successful-eradication-of-helicobacter-pylori-with-a-herbal-medicine-goshuyuto-wu-zhu-yu-tang-plus-rabeprazole-after-failure-of-triplet-therapy-with-vonoprazan-a-report-of-three-cases
#5
Yutaka Nagata, Kazuhiko Nagasaka, Syunpei Koyama, Mai Murase, Minoru Saito, Toshinori Yazaki, Nobutoshi Komatsu, Takayuki Murase, Toshiki Uehara, Norihide Taniuchi
Vonoprazan, a potassium-competitive acid blocker, is used as a substitute drug for conventional proton pump inhibitors. Recently, vonoprazan has been applied for eradication of H. pylori (HP) infection, and the efficacies of vonoprazan-based triple therapy against HP infection have already been reported. However, treatment sometimes fails in the primary and/or secondary triplet eradication therapy, including with the use of vonoprazan for HP infection. We experienced three cases of refractory HP infection. They were treated with eradication therapy for HP infection with chronic gastritis...
August 28, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28814829/antibiotic-susceptibility-heteroresistance-and-updated-treatment-strategies-in-helicobacter-pylori-infection
#6
REVIEW
Maria Teresa Mascellino, Barbara Porowska, Massimiliano De Angelis, Alessandra Oliva
In this review, we discuss the problem of antibiotic resistance, heteroresistance, the utility of cultures and antibiotic susceptibility tests in Helicobacter pylori (Hp) eradication, as well as the updated treatment strategies for this infection. The prevalence of antibiotic resistance is increasing all over the world, especially for metronidazole and clarithromycin, because of their heavy use in some geographical areas. Heteroresistance (simultaneous presence of both susceptible and resistant strains in different sites of a single stomach) is another important issue, as an isolate could be mistakenly considered susceptible if a single biopsy is used for antimicrobial tests...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28806959/second-line-therapy-for-helicobacter-pylori-eradication-causing-antibiotic-associated-hemorrhagic-colitis
#7
Kazuyuki Tanaka, Mikihiro Fujiya, Aki Sakatani, Shugo Fujibayashi, Yoshiki Nomura, Nobuhiro Ueno, Shin Kashima, Takuma Goto, Junpei Sasajima, Kentaro Moriichi, Toshikatsu Okumura
OBJECTIVE: Helicobacter pylori (H. pylori) eradication rarely develops into antibiotic-associated hemorrhagic colitis (AAHC), in which the etiology of colitis remains unclear. We herein report a rare case of AAHC caused by second-line therapy for H. pylori eradication. RESULTS: A 65-year-old female was administered second-line therapy for H. pylori composed of 1500 mg of amoxicillin, 500 mg of metronidazole and 40 mg of vonoprazan for 7 days because of first-line therapy failure...
August 14, 2017: Annals of Clinical Microbiology and Antimicrobials
https://www.readbyqxmd.com/read/28776748/editorial-replacing-standard-proton-pump-inhibitors-with-vonoprazan-may-breathe-new-life-into-triple-therapy-for-helicobacter-pylori
#8
EDITORIAL
A G Fraser
No abstract text is available yet for this article.
September 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28776746/editorial-replacing-standard-proton-pump-inhibitors-with-vonoprazan-may-breathe-new-life-into-triple-therapy-for-helicobacter-pylori-authors-reply
#9
EDITORIAL
Y S Jung, E H Kim, C H Park
No abstract text is available yet for this article.
September 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28776141/vonoprazan-based-helicobacter-pylori-eradication-therapy-time-to-get-kompetitive
#10
EDITORIAL
Eun Hye Kim, Chan Hyuk Park
No abstract text is available yet for this article.
August 3, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28664410/efficacy-of-vonoprazan-based-triple-therapy-for-helicobacter-pylori-eradication-a-multicenter-study-and-a-review-of-the-literature
#11
Hiroki Tanabe, Katsuyoshi Ando, Kiichi Sato, Takahiro Ito, Mitsuru Goto, Tomonobu Sato, Akihiro Fujinaga, Toru Kawamoto, Tatsuya Utsumi, Nobuyuki Yanagawa, Eiichiro Ichiishi, Takaaki Otake, Yutaka Kohgo, Yoshiki Nomura, Nobuhiro Ueno, Hiroko Sugano, Shin Kashima, Kentaro Moriichi, Mikihiro Fujiya, Toshikatsu Okumura
BACKGROUND: Eradication therapies for Helicobacter pylori infection are advancing as new acid inhibitory reagents approved. The aim of this study was to assess the efficacy and safety of vonoprazan-based triple treatment. MATERIALS AND METHODS: Triple therapy with vonoprazan and two antibiotics (amoxicillin and clarithromycin or metronidazole) received focus in this analysis. We performed a multicenter retrospective study of patients who received vonoprazan-based eradication therapy between February 2015 and February 2016 and conducted a review of the literature...
June 29, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28662503/the-effects-of-switching-to-vonoprazan-a-novel-potassium-competitive-acid-blocker-on-gastric-acidity-and-reflux-patterns-in-patients-with-erosive-esophagitis-refractory-to-proton-pump-inhibitors
#12
Hiroshi Yamashita, Atsushi Kanamori, Chise Kano, Hiroki Hashimura, Kei Matsumoto, Masahiro Tsujimae, Tetsuya Yoshizaki, Kenji Momose, Daisuke Obata, Takaaki Eguchi, Mikio Fujita, Akihiko Okada
BACKGROUND/AIM: The effects of vonoprazan and proton pump inhibitors (PPIs) in patients with reflux esophagitis (RE) have not yet been compared using multichannel intraluminal impedance-pH (MII-pH). METHODS: A total of 8 patients with persistent gastric mucosal injury, despite completing an 8-week standard PPI therapy, were enrolled in the study. While they were on standard PPI therapy, the baseline values of reflux parameters, holding time ratio (HTR) of gastric pH >4, and esophageal pH <4 were obtained by using 24 h MII-pH monitoring...
2017: Digestion
https://www.readbyqxmd.com/read/28657473/vonoprazan-fumarate-for-the-management-of-acid-related-diseases
#13
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli, Edoardo Savarino
Proton pump inhibitors (PPIs) display a number of limitations and unmet clinical needs that have prompted the development of novel drugs to improve the outcomes of acid-related diseases, including the eradication of H. pylori. In this context, a new synthesized potassium-competitive acid blocker (P-CAB), vonoprazan, showed higher suppression of gastric acid secretion. Areas covered: This review discusses the current knowledge regarding the efficacy of vonoprazan in the treatment of acid-related diseases, with a particular focus on its use in Helicobacter pylori eradication...
August 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28584402/effects-of-patient-age-and-choice-of-antisecretory-agent-on-success-of-eradication-therapy-for-helicobacter-pylori-infection
#14
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima
The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB...
May 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/28578848/study-on-pharmacokinetics-and-bioequivalence-of-vonoprazan-pyroglutamate-in-rats-by-liquid-chromatography-with-tandem-mass-spectrometry
#15
Yuan Qiao, Jun Zhao, Xuanfeng Yue, Yang Zhang, Ruitao Zhang, Yuan Xu, Xiuling Tang, Xueying Liu, Qingwei Wang
Vonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs). However, the clinical applications of TAK0-438F suffers limitation due to the lack of injection dosage form. Efforts to overcome this limitation lead to the systhesis of Vonoprazan pyroglutamate (TAK-438P) for its high water solubility and more potent antisecretory effect. This was the first report to establish and validate a reliable and sensitive LC-MS/MS method for the quantification of TAK-438P in rat plasma and tissues (heart, liver, spleen, liver, kidney, rain, stomach and small intestine)...
August 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28567114/a-randomized-double-blind-study-to-evaluate-the-acid-inhibitory-effect-of-vonoprazan-20-mg-and-40-mg-in-patients-with-proton-pump-inhibitor-resistant-erosive-esophagitis
#16
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida
BACKGROUND: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs. We aimed to evaluate the acid-inhibitory effects and efficacy of a novel potassium-competitive acid blocker (vonoprazan) in patients with PPI-resistant EE. METHODS: This randomized, double-blind, multicenter study of vonoprazan evaluated gastric and esophageal pH over a 24-hour period as the primary endpoint and EE healing rate as the secondary endpoint...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28566587/the-superiority-of-vonoprazan-based-first-line-triple-therapy-with-clarithromycin-a-prospective-multi-center-cohort-study-on-helicobacter-pylori-eradication
#17
Soichiro Sue, Hirofumi Kuwashima, Yuri Iwata, Hiroyuki Oka, Isao Arima, Takehide Fukuchi, Katsuyuki Sanga, Yasuhiro Inokuchi, Yuniba Ishii, Masatomo Kanno, Masahiro Terada, Hitoshi Amano, Makoto Naito, Shigeru Iwase, Hiroshi Okazaki, Kazuto Komatsu, Atsushi Kokawa, Ichiro Kawana, Manabu Morimoto, Toshifumi Saito, Yosuke Kunishi, Akihiko Ikeda, Daisuke Takahashi, Haruo Miwa, Tomohiko Sasaki, Toshihide Tamura, Masaaki Kondo, Wataru Shibata, Shin Maeda
Objective We evaluated the safety and efficacy of vonoprazan-based amoxicillin and clarithromycin 7-day triple therapy (VAC) in comparison to proton pump inhibitor (PPI)-based (PAC) as a first-line treatment and vonoprazan-based amoxicillin and metronidazole 7-day triple therapy (VAM) in comparison to PPI-based (PAM) as a second-line treatment for the eradication of Helicobacter pylori in Japan. Methods We performed a non-randomized, multi-center, parallel-group study to compare first-line VAC to PAC and second-line VAM to PAM...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28529929/novel-and-effective-therapeutic-regimens-for-helicobacter-pylori-in-an-era-of-increasing-antibiotic-resistance
#18
REVIEW
Yi Hu, Yin Zhu, Nong-Hua Lu
Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments...
2017: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/28501868/factors-associated-with-potassium-competitive-acid-blocker-non-response-in-patients-with-proton-pump-inhibitor-refractory-gastroesophageal-reflux-disease
#19
Masatsugu Okuyama, Kenichi Nakahara, Narika Iwakura, Tomoki Hasegawa, Maizumi Oyama, Ayumi Inoue, Hirotaka Ishizu, Hiroshi Satoh, Yasuhiro Fujiwara
BACKGROUND/AIMS: Approximately 20-40% of patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) treatment. The acid-inhibitory effect of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), is significantly greater when compared to the effect of PPIs. We investigated the efficacy of vonoprazan treatment for PPI-refractory GERD and factors associated with P-CAB non-response. METHODS: We enrolled 277 GERD patients receiving continuous PPI therapy...
2017: Digestion
https://www.readbyqxmd.com/read/28497487/systematic-review-with-meta-analysis-the-efficacy-of-vonoprazan-based-triple-therapy-on-helicobacter-pylori-eradication
#20
REVIEW
Y S Jung, E H Kim, C H Park
BACKGROUND: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. AIM: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. METHODS: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK-438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori...
July 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"